At the International Liver Congress in Amsterdam, US biotech company Gilead Sciences (Nasdaq: GILD) has presented clinical research data from its hepatitis B program.
Gilead announced positive 96-week results from two ongoing Phase III studies evaluating the safety and efficacy of daily Vemlidy (tenofovir alafenamide) in certain hepatitis B patients.
Vemlidy is a novel, targeted ‘prodrug’ of tenofovir that the company is comparing with Viread (tenofovir disoproxil), another hepatitis B medicine.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze